These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38353963)

  • 1. Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis.
    Blauvelt A
    JAMA Dermatol; 2024 Mar; 160(3):370. PubMed ID: 38353963
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral Upadacitinib Beats Subcutaneous Dupilumab for Atopic Dermatitis.
    Slomski A
    JAMA; 2021 Oct; 326(13):1246. PubMed ID: 34609462
    [No Abstract]   [Full Text] [Related]  

  • 3. Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis.
    Hayama K; Fujita H
    Dermatol Ther; 2022 Jul; 35(7):e15575. PubMed ID: 35536445
    [No Abstract]   [Full Text] [Related]  

  • 4. Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real-World Study on Effectiveness and Safety in Dupilumab Nonresponders.
    Zhao M; Zhuang Y; Liang Y; Ma L; Shen C
    Clin Exp Allergy; 2024 Sep; 54(9):694-696. PubMed ID: 39048775
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment.
    Gori N; Ippoliti E; Antonelli F; Peris K; Chiricozzi A
    Clin Exp Dermatol; 2023 Apr; 48(5):558-559. PubMed ID: 36724039
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study.
    Huang D; Lu J; Tan F
    Dermatitis; 2024; 35(1):77-83. PubMed ID: 37930745
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab.
    Cioppa V; Lazzeri L; Carraro A; De Piano E; Falcinelli F; Galluzzo M; Pallotta S; De Pità O; Russo F
    Dermatitis; 2024; 35(S1):S107-S108. PubMed ID: 37594754
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
    Mastorino L; Gelato F; Richiardi I; Cavaliere G; Quaglino P; Ortoncelli M; Ribero S
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e691-e692. PubMed ID: 36688263
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.
    Sánchez-García V; Navarro-Triviño FJ; Silvestre JF
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1426-e1429. PubMed ID: 37458506
    [No Abstract]   [Full Text] [Related]  

  • 11. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol; 2023 Jul; 189(2):e39. PubMed ID: 37459131
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: A multicenter retrospective study.
    Georgakopoulos JR; Sheka D; Rankin B; Maliyar K; Rimke A; Prajapati VH; Yeung J
    J Am Acad Dermatol; 2023 Dec; 89(6):1308-1311. PubMed ID: 37648068
    [No Abstract]   [Full Text] [Related]  

  • 13. Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study.
    Lasheras-Pérez MA; Palacios-Diaz RD; González-Delgado VA; Cobreros LV; Pereira-Resquin Galván GO; Miquel-Miquel J; Labrandero Hoyos C; Zaragoza Ninet V; Melgosa Ramos FJ; Sánchez-Motilla JM; Navarro-Blanco F; Martín-Torregrosa D; Botella-Estrada R; Rodríguez-Serna M
    Int J Dermatol; 2024 Mar; 63(3):402-404. PubMed ID: 38229523
    [No Abstract]   [Full Text] [Related]  

  • 14. Atopic Dermatitis and Difficult-to-Treat Areas: A Case Series of Four Patients With Dupilumab-Resistant Primary Atopic Blepharitis and Successfully Treated With Upadacitinib.
    Licata G; Tancredi V; Calabrese G; Arisi M; Ariasi C; Mariarosaria Giorgio C
    Dermatitis; 2024; 35(4):409-410. PubMed ID: 37910788
    [No Abstract]   [Full Text] [Related]  

  • 15. Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib.
    Licata G; Gambardella A; Tancredi V; Calabrese G; De Rosa A; Alfano R; Argenziano G
    J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):e150-e152. PubMed ID: 34553800
    [No Abstract]   [Full Text] [Related]  

  • 16. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythrodermic atopic dermatitis resistant to dupilumab and baricitinib successfully treated with upadacitinib.
    Valente C; Duarte B
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e493-e495. PubMed ID: 36306182
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-life efficacy and safety of upadacitinib in adolescents with moderate-to-severe atopic dermatitis unresponsive to dupilumab: A case series.
    Patruno C; Fabbrocini G; Potestio L; Genco L; Napolitano M
    J Eur Acad Dermatol Venereol; 2023 Jul; 37(7):e901-e903. PubMed ID: 36883801
    [No Abstract]   [Full Text] [Related]  

  • 19. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Gurioli C; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Esposito M; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e384-e388. PubMed ID: 36225088
    [No Abstract]   [Full Text] [Related]  

  • 20. Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study.
    Zhou B; Peng C; Cao Q; Wang J; Chen X; Li J
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e35-e38. PubMed ID: 37565387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.